Wang Shang-Jui, Haffty Bruce
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ 08901, USA.
Cancers (Basel). 2018 Dec 14;10(12):515. doi: 10.3390/cancers10120515.
Recent development in radiation biology has revealed potent immunogenic properties of radiotherapy in cancer treatments. However, antitumor immune effects of radiotherapy are limited by the concomitant induction of radiation-dependent immunosuppressive effects. In the growing era of immunotherapy, combining radiotherapy with immunomodulating agents has demonstrated enhancement of radiation-induced antitumor immune activation that correlated with improved treatment outcomes. Yet, how to optimally deliver combination therapy regarding dose-fractionation and timing of radiotherapy is largely unknown. Future prospective testing to fine-tune this promising combination of radiotherapy and immunotherapy is warranted.
放射生物学的最新进展揭示了放射疗法在癌症治疗中具有强大的免疫原性。然而，放射疗法的抗肿瘤免疫效应受到同时诱导的辐射依赖性免疫抑制效应的限制。在免疫治疗不断发展的时代，将放射疗法与免疫调节药物联合使用已显示出可增强辐射诱导的抗肿瘤免疫激活，这与改善治疗效果相关。然而，关于放射治疗的剂量分割和时间安排如何优化联合治疗在很大程度上尚不清楚。未来有必要进行前瞻性试验，以微调这种有前景的放射疗法与免疫疗法的联合应用。
